Major Program
Phase 0 I II Cancer Prevention Clinical Trials Program
Research Group
Lung and Upper Aerodigestive Cancer
Sponsor
National Cancer Institute (NCI)
Status
Completed
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT02237183
This phase I trial studies the side effects and best dose of iloprost compared with a placebo in preventing lung cancer in former smokers. Chemoprevention is the use of drugs to keep cancer from forming or coming back. Inhaled iloprost may help prevent lung cancer from forming in patients who used to smoke and who have been found to have abnormal cells in their mucus.
Intervention
Iloprost, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Condition
Lung Carcinoma
Investigators
York E Miller